Pancreatic neuroendocrine tumors: are AJCC and ENETS TNM stages valid for prognosis?

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Tumor node metastasis (TNM) staging systems proposed by the American Joint Committee on Cancer (AJCC) and the European Neuroendocrine Tumor Society (ENETS) appear to accurately predict progression-free survival (PFS) of pancreatic neuroendocrine tumors (pNETs).

Key results

  • According to AJCC staging, 2-year PFS was 92% for stage I, 61% for stage II, 60% for stage III, and 20% for stage IV (p<.01).
  • According to ENETS staging, 2-eyar PFS was 94% for stage I, 87% for stage II, 49% for stage III, and 20% for stage IV (p<.01).
  • ...